Log in
Enquire now
Omrix Biopharmaceuticals

Omrix Biopharmaceuticals

A company developing and manufacturing biosurgical and immunotherapy products

OverviewStructured DataIssuesContributors

Contents

omrix.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biotechnology
Biotechnology
Healthcare
Healthcare
Science
Science
Medical software
Medical software
Biopharmaceutical
Biopharmaceutical
Technology
Technology
...
Location
Illinois
Illinois
AngelList URL
angel.co/omrix-biop...maceuticals
Legal Name
Omrix Biopharmaceuticals, Inc.
Number of Employees (Ranges)
501 – 1,000
Full Address
14 Einstein St., Weizman Science Park, Ness Ziona, IL
CIK Number
1,349,4260
Place of Incorporation
Delaware
Delaware
0
Investors
Hercules Capital
Hercules Capital
Catalyst Fund LP
Catalyst Fund LP
IRS Number
522,147,0050
Founded Date
1995
Total Funding Amount (USD)
4,840,000
Latest Funding Round Date
March 31, 2005
Acquisition Transaction
‌
Acquisition of Omrix Biopharmaceuticals by Johnson & Johnson
Patents Assigned (Count)
52
Wellfound ID
omrix-biopharmaceuticals

Other attributes

Acquirer
Johnson & Johnson
Johnson & Johnson
0
Company Operating Status
Active
Public/Private
Private
SIC Code
2,8360
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Omrix Biopharmaceuticals

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.